HC Wainwright Analysts Decrease Earnings Estimates for GALT

Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Investment analysts at HC Wainwright decreased their FY2027 earnings per share (EPS) estimates for Galectin Therapeutics in a research note issued to investors on Friday, November 15th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings of $1.25 per share for the year, down from their previous forecast of $1.29. HC Wainwright currently has a "Buy" rating and a $11.00 price objective on the stock. The consensus estimate for Galectin Therapeutics' current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Galectin Therapeutics' FY2028 earnings at $3.39 EPS.

Separately, StockNews.com cut shares of Galectin Therapeutics from a "hold" rating to a "sell" rating in a research report on Tuesday, November 12th.

Galectin Therapeutics Stock Down 2.9 %

GALT traded down $0.08 during trading hours on Monday, reaching $2.69. 174,039 shares of the company's stock traded hands, compared to its average volume of 146,036. The firm has a market capitalization of $167.53 million, a PE ratio of -3.68 and a beta of 0.62. Galectin Therapeutics has a 52-week low of $1.55 and a 52-week high of $4.27. The firm has a 50-day moving average price of $2.69 and a 200 day moving average price of $2.61.

Hedge Funds Weigh In On Galectin Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Galectin Therapeutics by 2.0% in the first quarter. Vanguard Group Inc. now owns 1,979,891 shares of the company's stock worth $4,732,000 after acquiring an additional 38,037 shares during the period. Traynor Capital Management Inc. boosted its stake in Galectin Therapeutics by 23.5% in the second quarter. Traynor Capital Management Inc. now owns 42,871 shares of the company's stock valued at $97,000 after acquiring an additional 8,164 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Galectin Therapeutics in the second quarter worth $146,000. Commonwealth Equity Services LLC increased its position in Galectin Therapeutics by 317.6% during the 2nd quarter. Commonwealth Equity Services LLC now owns 483,351 shares of the company's stock valued at $1,092,000 after buying an additional 367,610 shares in the last quarter. Finally, Rhumbline Advisers acquired a new stake in Galectin Therapeutics in the second quarter worth about $44,000. Institutional investors own 11.68% of the company's stock.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.